>

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week.

Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook for the future.

In a week of major sector announcements and crowded news airwaves, we are delighted that GEN chose to cover our story, and the full article can be read at the link below.

JPM 2024: NanoSyrinx Wields Original Bacterial Syringe IP for Protein Delivery

Read more news

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more
Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more

NanoSyrinx to feature in PwC’s Life Sciences Future50 Report

We are delighted to be showcased as one of the 50 companies in PwC UK’s  ‘Life Sciences Future 50’ report, illustrating the world-class science and innovation being led by the UK’s life sciences sector to solve some of the most important challenges in scientific research and human healthcare. Find out more here: https://bit.ly/3Fnw379

Read more